Resolute Capital Asset Partners’s Cidara Therapeutics CDTX Stock Holding History

Resolute Capital Asset Partners’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-37,315	Closed	-$8.24M	–	46
2025 Q4	$8.24M	Sell	37,315 -20,000	-35%	-$3.23M	3.98%	7
2025 Q3	$5.49M	Buy	57,315 +30,000	+110%	+$1.91M	2.87%	13
2025 Q2	$1.33M	Buy	+27,315	New	+$656K	0.7%	37

Resolute Capital Asset Partners's CDTX Position: Q1 2026 in Review

Resolute Capital Asset Partners sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 37,315 shares — an estimated $8.24M sold.

Resolute Capital Asset Partners first reported a position in CDTX in Q2 2025 and held it in 3 quarters. The position peaked at $8.24M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Resolute Capital Asset Partners reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Resolute Capital Asset Partners sold 37,315 Cidara Therapeutics shares in Q1 2026, an estimated $8.24M.
Resolute Capital Asset Partners first reported a position in Cidara Therapeutics in Q2 2025 and held it in 3 quarters.
Resolute Capital Asset Partners's Cidara Therapeutics position peaked at $8.24M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q1 2026, filed 15 May 2026.